A
groundbreaking triple-drug therapy has shown remarkable success in
eliminating pancreatic cancer tumors and preventing their recurrence in
multiple mouse models. By simultaneously blocking three key growth pathways,
The non-toxic treatment represents a promising new strategy to overcome the
disease’s notorious treatment resistance.
Targeting the
Cancer’s Survival Network
The research,
published in PNAS, addresses a critical weakness of current
treatments: cancer’s ability to find “another door” for survival when
one pathway is blocked. Senior author Carmen Guerra and her team
identified that when major growth drivers like KRAS (mutated in
nearly all pancreatic cancers) are inhibited, a backup protein called STAT3 becomes
highly active. The new therapy strategically combines drugs to block KRAS, a
related pathway, and STAT3 all at once.
The Three-Drug
Cocktail & Stunning Results
The therapy uses:
- Afatinib: An FDA-approved lung
cancer drug. - Daraxonrasib: A drug currently in
clinical trials. - A novel STAT3 inhibitor.
Tested across three
rigorous mouse models—including one using human tumor samples—the
combination completely eliminated pancreatic tumors. “You couldn’t even
see where the tumor was. The pancreas was completely healthy,” Guerra reported.
Critically, the cancer did not return for at least 200 days post-treatment,
and the therapy showed no debilitating side effects in the mice.
Why This
Breakthrough Matters
Pancreatic ductal
adenocarcinoma, the most common form, has a five-year survival rate of
just 13%, dropping to 1% in late stages. Standard chemotherapy
attacks all fast-dividing cells, causing severe side effects, and tumors
rapidly develop resistance. This targeted approach aims to outmaneuver the
cancer’s adaptability by shutting down its primary and emergency survival
routes simultaneously.
The Path Ahead:
Cautious Optimism
While the mouse
results are exceptional, researchers acknowledge the leap to human patients.
Some drugs in the cocktail, like afatinib, are known to cause side effects
(skin and GI issues) in people. The team is now working to develop
better-tolerated drugs that target the same pathways. Further testing in mouse
models with diverse genetic mutations is also planned to ensure broad
effectiveness.
Supportive Care
& Wellness for Patients:
Source Information:
This report is based on the peer-reviewed study in Proceedings of the
National Academy of Sciences (PNAS).
Affiliate Disclosure: This article includes affiliate links. We earn a commission on qualifying purchases, which supports our science and health journalism at no extra cost to you.
Read also: Curbing Your Drinking? Just 14 Drinks Per Week Raises Colon Cancer Risk 25%
Read also: Paris Hilton: How ADHD Became My Entrepreneurial Superpower